Items where authors include "Denton, C.P."
Article
Lescoat, A., Bellando-Randone, S., Campochiaro, C. et al. (9 more authors) (2023) Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine. The Lancet Rheumatology, 5 (11). e683-e694. ISSN 2665-9913
Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 62 (9). pp. 3133-3138. ISSN 1462-0324
Spiera, R. orcid.org/0000-0003-2911-6800, Kuwana, M. orcid.org/0000-0001-8352-6136, Khanna, D. orcid.org/0000-0003-1412-4453 et al. (28 more authors) (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 75 (9). pp. 1608-1618. ISSN 2326-5191
Lepri, G., Hughes, M., Allanore, Y. et al. (8 more authors) (2023) The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution. The Lancet Rheumatology, 5 (7). e422-e425. ISSN 2665-9913
Denton, C.P. orcid.org/0000-0003-3975-8938, De Lorenzis, E., Roblin, E. et al. (27 more authors) (2023) Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (1). rkad022. ISSN 2514-1775
Denton, C.P. orcid.org/0000-0003-3975-8938, del Galdo, F. orcid.org/0000-0002-8528-2283, Khanna, D. et al. (12 more authors) (2023) Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 62 (1). pp. 234-242. ISSN 1462-0324
Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology. ISSN 1462-0324
Kakkar, V., Assassi, S., Allanore, Y. et al. (4 more authors) (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6). pp. 357-364. ISSN 1040-8711
Hughes, M., Allanore, Y., Baron, M. et al. (13 more authors) (2022) Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology, 4 (11). e795-e803. ISSN 2665-9913
Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983
Bageghni, S.A., Hemmings, K.E., Yuldasheva, N.Y. et al. (11 more authors) (2019) Fibroblast-specific deletion of IL-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight, 4 (17). ISSN 2379-3708
Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324
Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967
Proceedings Paper
De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.